GLP-1 can be used against hyperglycemia and obesity in most T2DM diabetic patients by stimulating insulin secretion, inhibiting glucagon secretion, slowing gastric emptying, and promoting satiety [2]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.